Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,77
KB1,26
PKN105,8106,251,00
Msft-0,77
IBM-0,52
DCX70,9770,99-0,15
PFE2,01
15.12.2017 1:36:41
Indexy online
AD Index online
select
AD Index online
 

  • 14.12.2017
CymaBay (NASDAQ Cons)
Závěr k 14.12.2017 Změna (%) Změna (USD) Objem obchodů (ks)
7,99 -2,08 -0,17 336 320
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 15.12.2017
Popis společnosti
Obecné informace
Název společnostiCymaBay Therapeutics Inc
TickerCBAY
Kmenové akcie:Ordinary Shares
RICCBAY.O
ISINUS23257D1037
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.9.2017
Počet zaměstnanců k 31.12.2015 21
Akcie v oběhu k 31.10.2017 43 864 121
MěnaUSD
Kontaktní informace
Ulice7999 Gateway Blvd Ste 130
MěstoNEWARK
PSČ94560-1188
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon15 102 938 800
Fax15102939090

Business Summary: CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.
Financial Summary: BRIEF: For the nine months ended 30 September 2017, CymaBay Therapeutics Inc revenues increased from $0K to $4.8M. Net loss increased 14% to $22.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other (expense) income, Net decrease from $43K (income) to $5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.84 to -$0.72.
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations



  • Poslední aktualizace: 15.12.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardRobert Wills628.10.20158.10.2015
President, Chief Executive OfficerSujal Shah421.11.20176.12.2013
Senior Vice President, Chief Scientific OfficerCharles McWherter62
Vice President - Finance, Principal Financial Officer, Principal Accounting OfficerDaniel Menold4727.4.201727.4.2017
Vice President - Regulatory Affairs and Quality AssuranceKirk Rosemark4427.4.201527.4.2015
General Counsel, Corporate SecretaryPaul Quinlan534.12.20174.12.2017
Chief Medical OfficerPol Boudes583.3.20143.3.2014